MyFiziq secures reseller agreement with NuraLogix
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MyFiziq Limited (ASX: MYQ) reports it has completed its technological integration with Canadian based NuraLogix Corporation paving the way to sell the parties’ CompleteScan application to their prospective clients and current partners.
CompleteScan, previously known as CompleteHealth, is the result of the integration of the NuraLogix and MyFiziq platform that provides a facial and body scan in under two minutes. The world first patented solutions have been combined to expand the capabilities of their capture suite for the global market.
Thirty organisations have so far requested access to the CompleteScan solution for both user validation and commercial discussions.
With overwhelming interest in the combined application, MyFiziq have agreed to offer it to a broader audience than the initially outlined Serfaty Clinic in Brazil and WeSure in China.
The company will now see the application tested in multiple countries and jurisdictions around the world.
NuraLogix’s patented technology utilises a video camera, similar to that found on a smartphone to take a 30 second selfie video of your face. It determines a wide range of physiological and health related parameters such as: heart rate, heart rate variability, blood pressure, stress, cardiovascular disease risks and more.
The underlying technology is Transdermal Optical Imaging (TOITM) that extract blood flow information from the user’s face via the video.
This information is processed by advanced machine learning algorithms residing on NuraLogix’s cloud based Affective AI Engine called DeepAffexTM.
MyFiziq’s image dimensioning capabilities will be combined with DeepAffex and Transdermal Optical Imaging to form a never before seen total health screen from a mobile phone.
The combined digital capabilities and unique offering is a one of a kind solution that can be used by anyone 18 or over.
Vlado Bosanac, Chief Executive Officer of MyFiziq, said, “This is an extremely exciting partnership for both companies. Bringing our technologies together will not only create a one of a kind solution, furthermore it will, in my opinion, be unrivalled. When combining the two solutions, we form not only a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience.
“The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone. We will be releasing the demo app to multiple potential partners in China, Hong Kong, Singapore, UK, US, and Thailand.”
The non-invasive combined solution delivers complete privacy to the consumer, which culminates in the individual being given assessments on multiple levels, such as:
- Blood pressure
- Stress levels
- Heart rate
- Heart rate variability
- Irregular heartbeat
- Respiratory rates
- Emotion
- Total body fat
- Waist to height ratio
- Waist to hip ratio
- Cardiovascular disease risk
- Type 2 diabetes risk, and
- Stroke risk.
The resulting captures and data allow individual to understand their personal exposure to these diseases, which form up to 70% of deaths globally each year, not including the current pandemic. All publications and research have been published on the NuraLogix website.
Under the terms of the Formal Reseller Agreement, the parties will now commence commercially offering the CompleteScan demo app to third parties.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
